HAGEN, Germany, November 3 /PRNewswire/ -- The World Wide Web Consortium (http://www.w3.org) has appointed Peperoni Software GmbH as a Committee Member for the upcoming workshop on the future of social networking in January 2009.

Back in 2001 already, the German Peperoni Software GmbH (http://www.peperoni.de) from Hagen, has developed a platform for the mobile and fixed-line internet for mobile social networking named http://www.peperonity.com making them the formal inventors of mobile site building. Peperoni will join a total of approximately 12 committee members that will have the task to evaluate the most pressuring issues that social networking faces in a converging world.

SAN DIEGO, November 3 /PRNewswire/ --

Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer's disease. These studies demonstrate that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical trials in Q1 2009. Results of the studies will be presented at the 9th International Conference -- AD/PD 2009 -- Prague, Czech Republic, March 11-15, 2009.

About Avineuro Pharmaceuticals, Inc.:

LONDON, November 3 /PRNewswire/ --

TerreStar Europe Limited, a European mobile communications provider and an indirect, majority-owned subsidiary of TerreStar Corporation (Nasdaq: TSTR), today announced that Richard Vos has been named a Director. With over thirty years experience in the telecommunications and satellite industries, Vos brings tremendous experience and leadership to the TerreStar Europe team.

Vos was formerly Chairman of Inmarsat Ventures PLC, which he led from privatisation in 1999 to a private equity buyout in 2003. He also previously headed Satellite Investments for British Telecommunications plc; he was also Governor for the UK and Ireland on the Board of INTELSAT and served as Chairman of the Board 1998-99.

DONGYING CITY, China, November 3 /PRNewswire/ --

CNPV (NYSE Euronext: ALCNP) (China Solar Photovoltaic SA or the Company), a leading integrated manufacturer of solar photovoltaic products from the production of ingots, wafers and cells to the assembly of SPV modules, founded in 2006, today announced that it filed its first half year Interim Financial Report for the year 2008 ended June 30, 2008 with Alternext of Paris NYSE-Euronext on November 3, 2008. The half year Interim Financial Report can be accessed via the investor relations section of the Company's website at http://www.cnpv-power.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081103/CNM010LOGO )

Take a close look at that cheap piece of scrap iron before you toss it in the trash.  Wei-xian Zhang has a good use for it. Someday soon, much of the world might also.  Zhang, a professor of civil and environmental engineering, recently concluded a five-year research project in which he and his colleagues at Tongji University in Shanghai used two million pounds of iron to detoxify pollutants in industrial wastewater.

The fight against climate warming has an unexpected ally in mushrooms growing in dry spruce forests covering Alaska, Canada, Scandinavia and other northern regions, a new UC Irvine study finds.  When soil in these forests is warmed, fungi that feed on dead plant material dry out and produce significantly less carbon dioxide than fungi in cooler, wetter soil. This came as a surprise to scientists, who expected warmer soil to emit larger amounts of carbon dioxide because extreme cold is believed to slow down the process by which fungi convert soil carbon into carbon dioxide.

Why are some species of plants and animals favored by natural selection?   According to a UC Riverside-led research team, the answer lies in the rate of metabolism of a species – how fast a species consumes energy, per unit mass, per unit time.  The researchers studied 3006 species, the largest number of species ever analyzed in a single study. The species list encompasses much of the range of biological diversity on Earth – from bacteria to elephants, and algae to sapling trees. 

To the researchers' surprise, they found the mean metabolic rate of the species at rest fell on a narrow range of values – 0.3 to 9 Watts per kilogram. 

CALGARY, Canada, November 3 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers.

Prof. Hardev Pandha of the Royal Surrey Hospital, U.K., presented the results at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

Fourteen patients have been treated to date in the dose escalation portion of the trial and eleven patients are evaluable for response. The detailed results are summarized in the following table:

UTRECHT, Netherlands, November 3 /PRNewswire/ --

- Sara Lee to Source 26,500 Tons of Sustainable Coffee in 2009 - Tenfold Increase in Five Years, 30% Increase Compared to This Calendar Year

Sara Lee further increases its commitment to sustainable coffee as the company will buy 26,500 tons of certified coffee beans in 2009. That is approximately 30% more than in 2008 and a tenfold increase since the company formalised its sustainable sourcing commitment five years ago. Sara Lee is the world's third largest coffee roaster and sells its coffee blends under flagship brands such as Douwe Egberts, Senseo, Merrild, Maison du Café and Marcilla.

CALGARY, Canada, November 3 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its Phase I and Phase II U.K. combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials for patients with advanced cancers. The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The results were presented at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.